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Abstract
In this paper, I present an empirical model of learning under ambiguity in the
context of clinical trials. Patients are concern with learning the treatment e¤ect of
the experimental drug, but face the ambiguity of random group assignment. A two
dimensional Bayesian model of learning is proposed to capture patientsbeliefs on the
treatment e¤ect and group assignment. These beliefs are then used to predict patient
attrition in clinical trials. Patient learning is demonstrated to be slower when taking
into account group ambiguity. In addition, the model corrects for attrition bias in the
estimated treatment e¤ect.
I. Introduction
In this paper provides an empirical examination of learning under ambiguity in the
context of clinical trials. Bayesian models have been widely used to capture consumer
learning for experience goods [see Erdem and Keane (1996), Ackleberg (2006), Crawford and
Shum (2006), Coscelli and Shum (2004)]. Learning is accomplished by observing a series of
signals from a single known source and updating ones beliefs according to BayesRule. In
the case of clinical trials, the issue of learning is complicated by patient randomization into
experimental and control groups. Patients are uncertain as to their true group assignment
(the source of the signals); therefore, changes in health cannot be immediately attributed
toward the experimental treatment. I propose a two dimensional model of learning to explain
how patient beliefs on drug quality and group assignment evolve. In addition to changes in
health, the model uses side e¤ects to capture both an explicit price for participating in the
experiment and an implicit source of group information. Variation in the rate of side e¤ects
between treatment groups can be used by patients to infer group assignment. A secondary
goal of this paper is to use the structural model, along with side e¤ect experiences, to study
patient attrition. The model is used to answer the question, "how do patientsbeliefs a¤ect
attrition decisions and, consequently, treatment e¤ect estimates?"
Clinical trials serve as a powerful setting to study learning for several reasons. First,
randomization requires that treatment groups be composed of individuals with similar char-
acteristics and beliefs. Randomization allows the investigators to extrapolate that di¤erences
in health seen between the two groups at later intervals of the trial are due to treatment
e¤ects and not to unobserved variations in the groups. By the same token, di¤erences in
patientsbehavior observed in later stages of the trial could be used to infer patient learning.
Second, clinical trials o¤er an exclusive good (the experimental drug). Patients can only
gain experience with the product by participating in the trial. Observational data relies
on consumers exclusively shopping at the rms available within the sample, which may not
necessary hold. This property emphasizes the advantage experimental data has over obser-
1
vational data, where unobserved variables could potentially have a large e¤ect on learning.
Lastly, the common initial condition problem associated with dynamic models does not ap-
ply to a clinical trial. The parameters of the experiment are well dened at the onset of
the trial. Patients are informed of the initial treatment probability, the possible length of
treatment, and compensation prior to beginning the trial.
The model utilizes data from two clinical trials: (1) AZT as a treatment of HIV and
(2) Topamax as a treatment for alcoholism. The rst clinical trial is the AIDS Clinical
Trials Group (ACTG) 019. The ACTG 019 was conducted during the early stages of AIDS
research and is the primary clinical trial responsible for investigating the rst treatment for
HIV infection. The results of this clinical trial found AZT to be a viable treatment for
short-run improvements in the health of HIV patients. Few researchers have questioned the
e¢ cacy of AZT to treat HIV, but some are concerned with the safety of AZT, as 80% of the
patient sample in this experiment fail to complete the full 80 week treatment. The pattern
of attrition is unusual because patients in the treatment groups are observed to leave the
trial at a faster rate than patients in the placebo group. Figure 1 illustrates the survival
rate of each treatment group over the duration of the trial.
The second dataset studies the e¤ect of an anti-seizure medication, Topamax, on al-
coholism. The medication is found to alleviate some dependency on alcohol at the cost of
experiencing side e¤ects. Unlike the side e¤ects in the AZT trial, side e¤ects associated
with Topamax are generally mild and well tolerated. The attrition pattern in the Topamax
study has patients in the placebo group leaving at a higher rate than patients in the treat-
ment group. The second trial provides an interesting comparison between a life threatening
disease, AIDS, and a long term addiction, alcoholism. The two medications also di¤er in
the intensity of their side e¤ects.
The results of this paper demonstrate that patient learning is slower than previously
reported. The additional ambiguity faced by patients causes posterior treatment e¤ect
estimate to converge at a slower rate. The combination of side e¤ects and a group assignment
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uncertainty leads to early attrition in both trials, but later attrition is attributed to low
posterior means of the treatment e¤ect. The structural model also indicates that attrition
bias is present in both experiments. The placebo health trend is found to be over estimated
in the AZT trial and the treatment e¤ect is found to be under-estimated in the Topamax
study.
II. Literature Review
The relationship between attrition decisions and patient learning is initially studied by
Philipson and DeSimone (PD, 1997). PD recognize that if attrition behavior is the result
of an exogenous process, then randomization in RCTs should imply homogenous attrition
rates across treatment groups. The authors reject the null hypothesis of homogenous attrition
rates in a collection of clinical trials on substance abuse. This result motivates the study of
attrition as a utility maximizing decision.
The proposed model is an extension to Chan and Hamilton (CH, 2006) who investi-
gate attrition behavior in a clinical trial on HIV combination treatments (ddI, AZT+ddI,
AZT+ddC) with an active control (AZT alone). The authors o¤er a framework for evalu-
ating randomized experiments in light of subject learning. In this study, a structural model
of attrition incorporating patient learning is constructed and estimated. Side e¤ects enter
as unobservable group characteristics leading to disutility, but do not a¤ect patient learn-
ing. Subject learning is found to be rapid and signicant; however early attrition behavior
is inferred to be the result of unobserved negative side e¤ects. The authors nd evidence
that when accounting for unobserved side e¤ects, the treatment that maximizes utility is
not always the most medically e¤ective treatment.
The model of patient behavior described in this paper provides several extensions to
CH. The most signicant of these extensions is constructing a learning model to allow for
uncertainty in both group assignment and treatment e¤ect. A patients belief on group
assignment is allowed to a¤ect her attrition decision. In Chan and Hamilton (2006), the
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model of learning is one dimensional in that the patient is concerned about her health expec-
tations and not concerned about her group assignment. This non-trivial extension captures
changes in patients behavior associated with changes in the initial treatment probability.
For example, a patient who is initially informed that her chance of receiving the experimental
treatment is 90% is less likely to exit the trial than if she were given only a 10% chance. If
a patient believes she may receive the experimental drug with a 90% chance, then she may
remain in the trial longer for fear of forgoing actual treatment, even when initial health ben-
ets appears to be small. Second, the model incorporates observable side e¤ect experiences
as informative signals of treatment group assignment and a source of disutility for partici-
pating in the trial. Some clinical trials have gone as far as to include an active ingredient
in the placebo medication to mimic the side e¤ect present in the experimental medication
in order to reduce the likelihood of patients learning their treatment assignment1.
III. Data
Data from two clinical trials are used to evaluate patient learning. The rst dataset is
an experiment testing the e¤ectiveness of AZT to improve white blood cell counts in HIV
patients. The second clinical trial tests the e¤ect of the anti-seizure medication, Topamax,
on alcohol addiction. These two datasets provide a good comparison in that both are
double blinded placebo controlled trials, but the di¤erence in side e¤ect severity between
trials is large. In both cases, side e¤ects are modelled to provide information about group
assignment, but in the HIV trial the side e¤ects may provide a signicant level of disutility
forcing patients out of the trial regardless of the information content. The two experiments
also di¤er in disease severity because HIV patients in the 1980s had life expectancies, after
diagnosis, of 2.5 years, while alcoholics can have much longer expected life spans2.
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A. ACTG 019
The ACTG 019 is a double-blinded, placebo-controlled Phase III study carried out be-
tween 1987-19893. The study evaluates the e¢ cacy and safety of AZT at two daily doses
(500mg and 1500mg) to prevent or delay the progression of AIDS in persons with asymp-
tomatic HIV infection. The public measure of health is CD4 counts, which are white blood
cells in the body that identify and defend against infection. The HIV virus inhibits the
production of these white blood cells. A randomized controlled trial of 1,338 subjects was
conducted in which patients were given free medical services as compensation for their par-
ticipation in the trial. Patients are observed at baseline, 8, 16, 32, 48, 64, and 80 weeks.
ACTG 019 is a multicenter clinical trial drawing patients from 11 di¤erent states across the
nation4. Originally, 428 patients are randomized into the placebo group, 453 patients into
the low dose group, and 456 into the high dose group5.
The several measures of health are recorded such as counts for hemoglobin, platelets,
granulocytes, and CD4 white blood cells. In an e¤ort to control for sample selection into the
clinical trial, the investigators required that patients have a CD4 count  500 cells/mm3: At
the onset of the trial, 12% of the patients are found to t the AIDS criteria6. The pattern of
CD4 progression is illustrated in Figure 2. Initially, both experimental groups, on average,
have a greater improvement in health, but these improvements appear to dissipate towards
the end of the trial leaving the placebo group with the greatest improvement in overall
health.
The investigators also collect demographic information for each patient, which includes
the variables of race, sex, and method of initial infection. The descriptive statistics for these
measurements are found in Table 1. Given the randomization process in the clinical trial,
it is not surprising to nd similar measurements of the mean across treatment groups for
demographic variables. An important demographic to highlight is the method of infection.
The method of infection is classied into three groups: homosexual experience, bisexual
experience, and intravenous (IV) drug use. Over 70% of infections occurred through a
5
homosexual experience between 1986-89. In 2006, the highest prevalence of HIV infections
is among female heterosexuals (typically sex workers). Given the changes in the HIV
population, the reader should treat any pharmacological results found in this study with
some reserve.
Side e¤ect experiences are recorded. The side e¤ect measures are aggregated into two
classications: blood related side e¤ects and liver related side e¤ects. Blood related side
e¤ects include anemia, neutropenia, and thrombopenia. Liver side e¤ects include hepatic
toxins, elevated liver enzymes (SGOT, SGPT), and bilirubin. These side e¤ects are measured
via blood samples taken at xed intervals throughout the trial. For the purpose of this study,
side e¤ects are dened as the occurrences of negative health shocks, either blood or liver,
in any group. Traditionally, a side e¤ect is measured as the di¤erence in negative health
shocks between groups. The denition used here allows for side e¤ects to occur in the
placebo group. Placebo group side e¤ects are assumed to occur as natural events associated
with the disease. Side e¤ects are experienced by 30.4% of patients receiving treatment.
Side-e¤ects may convey information about treatment group assignment. To illustrate this
point, consider the di¤erence in anemia occurrences across treatment groups (see Table 1).
Clearly, if a patient does experience anemia, then she could infer that she is not in the
placebo group, as no one in the placebo group reports anemia as a side e¤ect.
All treatment groups experience substantial attrition with less than 20% of the sample
surviving to week 80. If attrition is an exogenous process, then attrition rates should be
identical across groups. In this sample, attrition rates are heterogenous and follow a specic
ordering from lowest to highest: placebo, low dose, and high dose. The average patient spell
is 33 weeks. The average patient spell within a treatment group is 28 weeks in the high
dose group, 34 weeks in the low dose, and 38 weeks in the placebo group.
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B. Topamax
The second dataset is from a randomized double blinded study testing the use of Topa-
max to treat alcohol dependence. Topamax (Topiramate) was originally approved by the
FDA in 1996 to treat seizures, but has recently been tested to treat various types of addiction
including alcoholism. In this study, 150 patients participate in a 12 week study where half
of the patients are randomly assigned to receive either placebo or Topamax. In addition
to the study medication, patients also participate in therapy sessions, receive free medical
services, and are given weekly compensation of $20 per visit. Prior to consent, patients
are informed of the possible risks including potential side e¤ects associated with Topamax,
which include drowsiness, dizziness, slurred speech, and slowing of motor skills.
The study collects both medical and demographic information about each patient. De-
mographic data includes drug use, employment status, race, age, height, weight, criminal
record, and family history. Table 2 provides a comparison of means for some observable
demographic variables. The average patient is a 42 year old male with a body mass index
(BMI) of 26.12, 13.53 years of schooling, and an annual income of $39,000. Most patients
hold at least a high school diploma and have careers in various working sectors including
Clerical and Sales (25%), Administration (24%), and Skilled Manual Labor (18%)7. The
racial prole of patients in this experiment is white (60%), Mexican (29%) and other (11%).
The distribution of race in this study is more a reection of location, Texas, than of the
population of alcoholics.
Alcohol dependence is monitored using a patients Gamma-glutamyl transferase (GGT)
level. The GGT test provides a better measure of alcohol dependence than a blood alcohol
level (BAL) measure because a patient would need to abstain from alcohol for 4-5 weeks to
reach normal GGT levels. A patient need only abstain from alcohol for several hours to
a¤ect the BAL measure. While GGT levels are initially higher in the experimental group
than the placebo group, the largest decrease in GGT levels are observed in the experimental
group. Baseline GGT values (81.8 Topamax and 65.3 Placebo) are compared with values
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recorded during the twelfth visit (57.8 Topamax, 52.5 Placebo)8.
The study documents side e¤ect events by recording the date of onset, duration, severity,
and action taken for each type of side e¤ect. The likelihood of experiencing at least one
side e¤ect is about the same in both groups, Topamax (47.33%) and Placebo (46%). The
average number of side e¤ects reported by patients in each group is 4.65 in Placebo, and 7.78
in Topamax. The most common side e¤ects experienced in the study are parasthesia (18%),
somnolence(16%), anxiety (13%), fatigue (12%), and weight loss (10%)9. Side e¤ects may
have both direct and indirect consequences on patient participation. The direct e¤ect of
side e¤ects is disutility associated with pain or discomfort. An indirect e¤ect associated with
side e¤ects is learning in that a patient may infer her group assignment through side e¤ect
experiences. For example, parasthesia is eight times more likely to occur in the treatment
group than in the placebo group. Uninformative side e¤ect signals include anxiety and
somnolence, as they are equally likely to occur in either treatment group.
Overall, 44% of placebo patients and 28% of Topamax patients exit the trial. On
average, patients are 9.7% more likely to leave the placebo group than the Topamax group
during any given week. A formal test where the null hypothesis is homogenous attrition
rates across groups is rejected at the 1% level using a paired Student t test (T= -4.96, p-value
= .001). Two probable reasons for heterogenous attrition rates are side e¤ects and learning.
If patients are sensitive to side e¤ects, then, holding all else equal, as side e¤ects increase, so
should the attrition rates of patients in the group experiencing side e¤ects more often. If side
e¤ects are the predominant factor of attrition, then one would expect to nd higher attrition
rates in the Topamax group instead of the placebo, but attrition is observed to be higher in
the placebo group. The second reason for heterogenous attrition rates is learning. Patients
receive signals on the treatment e¤ect of the drug through observed changes in health. If a
patient does not experience a signicant improvement in health, then she may infer that her
group assignment is placebo, and would exit the trial in favor of the outside medical option.
Attrition as a result of learning would lead to higher attrition rates in the placebo group, as
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is observed in the data.
IV. Structural Model
A. Experimental Design
This section describes the organization of a clinical trial, denes patient preferences,
and describes the mechanism of Bayesian Learning used to update beliefs. Clinical trials
are a type of experiment where participants are randomly selected into either a control or
treatment group, but are blinded (uncertain) to their actual group assignment. Random-
ization creates two groups, which are statistically identical, allowing researchers to attribute
future changes in health outcomes to treatment e¢ cacy, and not to di¤erences in group char-
acteristics. In this setting, treatment e¢ cacy is measured as the mean di¤erence in health
outcomes between the treatment group and the placebo group. The term "double-blinded"
implies that both physicians and patients are unaware of group assignment (treatment or
placebo). In principle, double blinding ensures that neither physicians, nor patients may
bias health outcomes through private motivations. Blinding introduces the ambiguity of
group assignment to the patient, which makes patient learning potentially valuable. Two
types of controls are commonly used in clinical trials: placebo and conventional control. A
placebo contains no active ingredient, while a conventional control contains an active ingre-
dient that is the approved standard of treatment outside of the trial. Therefore, patients
who participate in a placebo controlled trial are more motivated to learn their treatment
assignment than those who participate in standard control trials for fear of forgoing actual
treatment available outside of the trial.
At the onset of the trial, patients are made aware of the number of possible treat-
ments, the probability of receiving each treatment, treatment duration, and the type of
compensation. Patients receive free medical consultations and/or monetary allowances as
compensation for participating in the experiment. Once the trial has commenced, measure-
ments on patient health and side e¤ect experiences are taken at xed time intervals. At
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the end of each period, a patient may display one of two types of behavior: (1) exiting the
trial (attrition) or (2) remaining in the trial and consuming the prescribed amount of the
assigned drug (compliance)10.
B. Patient Preferences
Consider a clinical trial in which there are G treatment groups. Patients are randomly
assigned to treatment group g with a xed probability, 1=G: In each treatment period t,
patient i observes her health Higt, two side e¤ect measures (S1igt; S2igt), and the price of
the outside medical option, pit. Health and side e¤ects are assumed to be distributed joint
normal.
(1)
266664
Higt
S1igt
S2igt
377775 N
0BBBB@
266664
Hi0+it+gt
s1igt
s2igt
377775 ;
 =
266664
2" 1u1" 2u2"
1u1" 
2
u1 3u1u2
2u2" 3u1u2 
2
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377775
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Patients are assumed to know certain components of their health equation. In particular, a
patient knows her initial level of health,Hi0, the progression of the disease without treatment,
it = 1 + 2 (t  1) + ei, but is uncertain about the group specic experimental e¤ect,
gt = 3dg + 4 (t  1) 1g=treatment: After observing prices, health, and side e¤ects in a given
period, the patient decides whether to remain in the trial or consume the outside option.
Patients are assumed to be forward looking agents and make the discrete choice of
attrition by maximizing the expected discounted sum of future utility ows. A clinical
trial represents a nite horizon dynamic problem where decisions are made conditional on a
patients information set, I; at time (t)
(2) max
T 
E
"
T TP
=t
 t
GX
g=1
igtUig +
T

1  V
0 (T ; igt) jI
#
where a patients choice of attrition time is T   T (T represents the patient remaining
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in the trial), igt is patient is belief on being in treatment group g at time t, and  is the
discount factor. The outside option is dened as
(3) V 0 (t; jI) = c1 + c2t+ 1 + 2t + viot
where c, is a set of parameters to be estimated, capturing the utility of alternative medical
options available outside of the trial during each week . The value of the outside option is
also allowed to vary based on a patients group assignment beliefs through the parameters .
The term (c2 + 2) t captures long term e¤ects of participating in the trial: After observing
health and side e¤ects in a given period, the patient decides whether to remain in the trial
or consume the outside option11.
Let the single period utility function for a patient in group (g) be dened as
(4) Uigt =  1

exp ( Higt)  a1S1igt   a2S2igt + i + vigt
which is a constant absolute risk aversion (CARA) utility function with a linear portion
capturing side e¤ects and the opportunity cost of forgoing the outside option12 ; 13 ;14. The
parameters  and a represent the patients sensitivity to risk and side e¤ects, respectively.
The coe¢ cient of absolute risk aversion is given by the parameter  > 0. Risk is an
important aspect of learning models as there is a trade-o¤ to waiting an additional period
and forgoing the outside option to learn more about product quality. The outside option
represents a certainty equivalent o¤ered to the patient. When the certainty equivalent is
at least as large as the expected value of the utility ows, it is optimal for a risk averse
patient to choose the outside option. There are two sources of unobserved heterogeneity, i
and vigt. The rst error term, i, is a normally distributed person specic error with mean
zero that captures a patients unobserved value for participating in the trial. This error is
observed by the patient but unobserved by the econometrician. The second error term, vigt,
is assumed to be distributed Type I extreme value and captures unobserved changes on the
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patients outside option. This error is revealed to the patient at time t; but unobserved to
the econometrician.
A patients information set is dened as Iit = fHit;Sit; tg; where Hit = [Hi1 Hi0 i1 
ei; :::; Hit 1 Hi0 it 1 ei] is a patients health history and Sit = [S1i1;:::; S1it;S2i1;:::; S2it;]
is a patients side e¤ect history. A patient learns her specic experimental e¤ect, igt; and
treatment group assignment, igt; through an application of BayesLaw on the variables in
her information set.
C. Patient Learning Process
At the beginning of the trial, patients construct prior beliefs about drug quality.15. The
experimental e¤ect prior, ig0; is assumed to be distributed bivariate normal
(5) ig0 =

1i0
2ig0

~N
0B@
g0
=

10
2g0

; =
26421 0
0 22
375
1CA
where 10 is the prior dose e¤ect and 2g0 is the treatment group specic time trend.
Patients are informed on the initial randomization probability, g0 = 1=G, which serves
as their prior on treatment group assignment. Formally, igt = Pr(g = gijIit) where
g 2 fPlacebo, Low Dose, High Doseg in AZT study and g 2 fPlacebo, Treatmentg in the
Topamax study. The variable gi is a patients actual treatment group. Patients are assumed
to be Bayesian learners and use these priors to update their beliefs. Let posterior beliefs be
indicated with a superscript (0) :
If the treatment e¤ects for each group are known by the patients, but treatment assign-
ment is unknown, then BayesLaw can be used to learn group assignment. Let f() be the
probability density function of health for patients in group g. A patient updates her belief
on group assignment according to BayesLaw
(6) 0j=Pr (g = gjjx)=
jf(xjg = gj)PG
i=1 if(xjg = gi)
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where the posterior belief on group assignment, 0j; is dependent on both the relative like-
lihood of observing a series of signals, x; given the patient is in group g and the patients
prior belief of being in group g: Given the discrete nature of group assignment and the
continuous nature of health, patients initially assume health is drawn from a normal mixture
distribution. The normal mixture distribution is the weighted sum of G distinct normal
distributions
L
 
Hit; Sitjigt (Hit;Sit) ; igt (Hit;Sit) ;; s1g; s2g;


(7)
=
G=3X
j=1
igt (Hit;Sit)
Z
2

 
Hit; Sitj;
; s1g; s2g


 
jigt (Hit;Sit) ;; g = j

d
where  is the support of possible experimental e¤ect values (), L () is the likelihood
function over the unknown parameters,  () is the normal probability density function, and
treatment group beliefs are restricted to satisfy
PG
j=1 igt = 1. The normal mixture model
captures three concepts: [1] health within a group is normally distributed; [2] the patient
is uncertain as to the parameter values of the normal distribution(ie mean and variance of
health for di¤erent treatment groups); [3] the patient recognizes that there are G possible
processes generating her health outcomes.
Given the patients likelihood function on health, one would normally proceed by cal-
culating the posterior distribution on experimental e¤ects and treatment group assignment
conditional on an observed value of health. Unfortunately, a closed form solution to the
posterior distribution of equation (7) does not exist16. A continuous random variable re-
quires a conjugate prior for a closed form solution of the posterior distribution, but the
posterior distribution is always dened for discrete random variables. Therefore, I discretize
the probability state space dened by equation (7) for a nite number of health, side e¤ect,
and experimental e¤ect states conditional on group assignment and a patients priors17.
Once the probability space is discretized, an application of BayesLaw provides the joint
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posterior distribution on beliefs.
Pr


=
igt; 
=
igtjHit;Sit;; s1g; s2g;


=
wigt
 
 = igt
P
G
P
wigt ()
(8)
wigt () = Pr(Hit;Sitj; s1g; s2g;
; igt 1 = 1)Pr(jg0;; igt 1 = 1)Pr(igt 1 = 1)
For each patient, I store a set of probabilities corresponding to each


=
igt; 
=
igt

beliefs pair.
The set of probabilities provides a nite approximation to the continuous joint distribution
described in (7). As the number of pairs tends to innity, the discrete approximation
converges towards the continuous distribution. Given the joint posterior distribution on
beliefs, a patients expected utility is dened as
(9) Et [U jIit] =
X
G
X

U


=
igt; 
=
igt

Pr


=
igt; 
=
igtjHit;Sit;; s1g; s2g;


where the expectation is taken over all the possible treatment group and experimental e¤ect
states conditional on a patients information set at time t. Patients must also consider future
values on utility. Therefore, a predictive posterior distribution is required to evaluate the
expected value of utility at time t+k for k>0. The k period predictive posterior distribution
is
Et [U jIit+k] =
X
G
X

U


=
igt+k; 
=
igt+k

(Vigt+k) (Hit+k;Sit+k)
Vigt+k =
"X
H
X
S
Pr


=
igt+k; 
=
igt+kjHit+k;Sit+k;; s1g; s2g;

#
(10)
 (Hit+k;Sit+k) = Pr(Hit+k;Sit+kjbg; lg;
; =igt+k 1; =igt+k 1) Pr


=
igt+k 1; 
=
igt+k 1

where  (Hit+k;Sit+k) is the distribution of future health outcomes conditional on having the
belief pair of


=
igt+k 1; 
=
igt+k 1

and Vigt+k is the probability of observing the belief pair of

=
igt+k 1; 
=
igt+k 1

conditional on past health outcomes: A patient iterates the predictive
posterior distribution to evaluate the expected value of future utility k periods into the
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future.
Illustration. Consider the following example of learning under ambiguity. Assume
a hypothetical clinical trial with two groups, two experimental e¤ects, and two outcomes for
each observable health variable. The health variable, A, is equal to 1 if the patient has AIDS,
and zero otherwise; S is equal to 1 if the patient experiences a side e¤ect, and zero otherwise.
Initially, patients are randomized into either the placebo (P ) or experimental (E) group
with Pr(P ) = 0:5. There are two possible treatment types within each group, ulow < uhigh.
The probability of observing a low experimental e¤ect in the placebo (experimental) group
is Pr (u = ulowjP ) = :8 (Pr (u = ulowjE) = :2). These probabilities serve as the patients
initial prior on the distribution of groups and treatment types. Lastly, the likelihood of
observing any pair of health outcomes conditional on treatment type and group is given by
a discrete distribution found in each column within the table below18.
Pr(P)=.5 Pr (E)=.5 Total
Pr(ulowjP)=.8 Pr(uhighjP)=.2 Pr(ulowjE)=.2 Pr(uhighjE)=.8
A=0 S=0 (.1) (.8) (.5) (.2) (.2) (.5) (.2) (.2) (.5) (.2) (.8) (.5) .16
A=1 S=0 (.6) (.8) (.5) (.5) (.2) (.5) (.1) (.2) (.5) (.1) (.8) (.5) .34
A=0 S=1 (.1) (.8) (.5) (.1) (.2) (.5) (.5) (.2) (.5) (.6) (.8) (.5) .34
A=1 S=1 (.2) (.8) (.5) (.2) (.2) (.5) (.2) (.2) (.5) (.1) (.8) (.5) .16
Total .4 .1 .1 .4 1
A patient improves her utility by increasing her health and decreasing her uncertainty.
A patient is uncertain as to which group and treatment type she is (i.e. in which cell
of the matrix she is). She resolves this uncertainty by using Bayes rule to update her
beliefs about treatment type and group19. The probability of a given (treatment type,
group) pairing is captured by a binomial distribution. The prior variance over beliefs
is var(G; u) = :6620. If the patient observes the health outcome {A=1,S=0}, then her
posterior beliefs on the joint probability of being both in the placebo group and experiencing
a low health return is Pr(ulow; P ) =
Pr(A=1 S=0julow;P )
Pr(A=1 S=0)
= 0:7059. The posterior variance over
15
beliefs becomes var(G; u) = :4654. There are a few noteworthy points about this exercise.
First, the exercise illustrates that learning can decrease patient uncertainty, thus improving
patient utility. Second, the exercise reinforces the need to model the joint distribution of
treatment types and group assignment. Initially, treatment types and group assignments
are distributed independently (as in the table above), but after receiving the rst signal the
posterior probability of a low treatment type is dependent on the posterior group assignment
belief (the table below).
Placebo Experimental Total
ulow uhigh ulow uhigh
A=0 S=0 (.1) (.7059) (.2) (.1470) (.2) (.0295) (.2) (.1176) .1294
A=1 S=0 (.6) (.7059) (.5) (.1470) (.1) (.0295) (.1) (.1176) .5118
A=0 S=1 (.1) (.7059) (.1) (.1470) (.5) (.0295) (.6) (.1176) .1706
A=1 S=1 (.2) (.7059) (.2) (.1470) (.2) (.0295) (.1) (.1176) .1882
Total .7059 .1470 .0295 .1176 1
D. Value Function
Given the learning model described in the previous section, the attention is returned to
the patients dynamic discrete choice problem. The experimental design of a clinical trial
lends itself to the use of a dynamic discrete choice framework to model attrition behavior.
Patients are informed of the start and end dates of the experiment. Patients are informed
of the type of compensation they may receive and the discontinuance of compensation if
they are to exit the trial without the option to return. Each period, the patient may
take one discrete action, compliance or attrition. Given the patients information set,
Xit =

0igt; 
20
igt; 
0
igt; t; ei; i

, a patients value function for remaining in the trial at treatment
period t can be represented by the following value function Vt (Xit) = max
DTDt
V (Xit; DT )
where DT  = [dt = 0; dt+1 = 0; ::dT  = 1; ::dT = 1] is the unique sequence of discrete choices
such that patient i expects to exit the trial at time T   T: The sub-value function,
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V (Xit; DT ) ; is dened
(11) V (Xit; DT ) = Et [U jXit] + Ev

max
 
Ex [V (Xit+1; DT ) jXit] ; V 0 (t+ 1; 0jI)

and the value function in the last period, T; is V (XiT ; DT ) = Et [U jXiT ] : The discount
factor  2 [0; 1) represents the patience of a patient between periods, where individuals with
low values of  place greater weight on the current level of utility rather than future levels
of utility. The case of  = 0 is the myopic patient who only maximizes current utility ows.
The case of  = 0:98 is the "forward looking" patient who values learning more than the
myopic patient. A forward looking patient is willing to trade low health returns in the early
stages of the trial for more health signals. These additional signals are used to update beliefs
and reduce uncertainty, thus increasing utility. In this paper, I examine learning under both
specications of the discount factor. The expectations in equation (11) are rst taken over
the distribution of beliefs, and then taken over the future values of vigt21: Recalling that
vigt  EV

0; 
22
6

, a closed form solution for the expected value of the future periods
value function exists as
Ev

max
 
Ex

V (Xit+1; DT )  vigt+1jXit

; 0

(12)
= 
"
  + ln
 
1 + exp
"
Ex

V (Xit+1; DT ) jXit


#!#
where V (Xit+1; DT ) = V (Xit+1; DT )  vigt+1; and   is the Euler constant22. The optimal
value function can be solved by rst taking the expectation with respect to beliefs, and then
using (12) to solve (11) backward recursively for each value of T : Finally, the value of T 
that maximizes V (Xit; DT ) is the optimal value function, Vt (Xit).
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V. Econometric Specication
A. Basic model
This section presents the econometric method used to estimate the attrition model.
The likelihood function is comprised of two parts: attrition decisions and the distribution
of outcome measurements. In the previous section, a patients value function is dened
as V (Xit; DT ) = V (Xit; DT )   vigt; where Xit =

0igt; 
20
igt; 
0
igt; t; ei; i

; V () is a latent
variable, and dit 2 DT  is the observed binary choice, where dit = 1 when the patient exits
the trial, and 0 otherwise. The error term, vigt; is assumed to be distributed Type I extreme
value. The error terms ei and i are patient specic errors known to the patient, but
unknown to the econometrician. These errors are assumed to be distributed iid normal with
variance equal to 2e and 
2
 ; respectively.
Given the distribution of the errors, the conditional survival probabilities at time t are
Pr(dit = 0jdit 1 = 0; ei; i) =
exp
 
V it=

1 + exp
 
V it=
(13)
Pr(dit = 1jdit 1 = 0; ei; i) =
1
1 + exp
 
V it=

Pr(dit = 0jdit 1 = 1; ei; i) = 0
Pr(dit = 1jdit 1 = 1; ei; i) = 1
The "no re-entry" policy of an RCT is captured by the last two equations. The unconditional
probability of attrition at time t is then given by equation (13)
(14) Pr(dit = 1jei; i) =
1
1 + exp
 
V it=
  "t 1Y
j=1
exp
 
V ij=

1 + exp
 
V ij=
#
The second part of the likelihood function is the distribution of health and side ef-
fects. Dene the vector of deviations between observed and predicted outcomes as Zit =
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[ei + "ig1; ei + "ig2; :::ei + "igt; u1ig1; :::; u1igt; u2ig1; :::; u2igt]
0 : The deviations are stacked in
the following order: health, blood related side e¤ects, and liver related side e¤ects. Given
the assumption of joint normality between health and side e¤ects, the probability density
function of patient is outcome measurements is given by
(15) f (Zit;
) =
1
(2)3t=2 j
j1=2
exp

 1
2
Z 0it

 1Zit

where t is the period when patient (i) exits the trial, and 
 is the health covariance matrix.
The total number of observations for patient i is equal to 3t as there are three measures of
outcomes taken over the t treatment periods.
Dene the set of parameters to be estimated as 	 = f; bg; lg;
;; pg; a1; a2; ; ; 2 ; g.
The likelihood contribution of the ith patient conditional on the unobservable errors is
(16) Li (	jdit;Hit;Sit; ei; i) = f (Zit;
jdit = 1; ; bg; lg)  Pr (dit = 1jei; i;	)
To remove the unobserved heterogeneity, an expectation of the likelihood contribution is
taken over the distributions of the unobserved heterogeneity errors.
E (Li (	jdit;Hit;Sit; ei; i))(17)
= f (Zit;
jdit = 1)
Z Z
Pr (dit = 1jei; i;	) f (ei) dei

f (i) di
While no closed form solution exists for the expected value in equation (17) ; I employ
simulation methods as suggested by Stern (1994) to integrate out the unobserved patient
specic heterogeneity. The simulated value of the log likelihood function is given by
(18) log bLi (	jdit;Hit;Sit) = log 1
R2
RX
r=1
RX
k=1
Li (	jdit;Hit;Sit; er; k)
!
and the parameters of the dynamic model are estimated by max
	
log
Pn
i=1
bLi (	jdit;Hit;Sit).
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B. Identication
The identication of the structural parameters can be divided into three parts: treat-
ment e¤ect parameters, learning parameters, and utility parameters. The variables of
interest (CD4 and GGT) and side e¤ects are assumed to be distributed joint normal23.
Treatment e¤ect parameters are identied through variation in observed health and side ef-
fect measures conditional on the patient remaining in the trial. The rst moments of these
variables identify the treatment e¤ect and mean side e¤ect levels. The placebo or baseline
health parameters are identied jointly through the health equation and patient attrition de-
cision. A necessary exclusion restriction is to assume that patients know their baseline health
parameters, it = 1+ 2 (t  1)+ ei. Further, the placebo treatment e¤ect, placebo;t = 0; is
set to zero. The model can only identify relative di¤erences in health between groups. By
normalizing the placebo treatment e¤ect to zero, the absolute experimental treatment e¤ect
is identied instead of the relative treatment e¤ect. The treatment e¤ect parameters, g;t;
only enter the health equation (treatment beliefs enter into the attrition decision), but the
baseline health parameters, it, and unobserved health errors enter into both the attrition
model and the health equation.
Identication of the learning parameters relies on the randomization process found in the
experiment design. Patient randomization creates statistically identical treatment groups
in both demographics and beliefs. In the absence of learning and controlling for side e¤ects,
attrition behavior should remain the same across groups. Therefore, learning is identied via
heterogenous attrition behavior between groups after controlling for side e¤ects. The prior
constant and prior time treatment e¤ect are separately identied. A patient needs at least
two signals to update the prior time treatment e¤ect (two signals are needed to calculate a
slope), thus attrition occurring after receiving the rst signal (week 3), but before the second
signal (week 6) identies the time treatment e¤ect. The remaining residual in attrition rates
across all time periods identies the prior constant.
The parameters in the utility function are identied by co-variation in observed health,
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side e¤ects, and attrition decisions. The parameter of constant absolute risk aversion, ;
is identied by changes in attrition associated with a patients posterior beliefs (treatment
e¤ect and group assignment) and the functional form of the utility function. The value of
the outside option is identied by variation in the external price of treatment and attrition
decisions a¤ecting all treatment groups equally. The variance of the extreme value error,
v, is separately identied only in the dynamic model,  > 0; via the functional form of the
continuation value in the value function of remaining in the trial (see equation 12). In the
static model,  = 0, the variance of the extreme value error is not separately identied from
the utility function parameters. In this case, the variance term is set equal to the estimated
value of the variance found from the dynamic model. The variances of the unobserved
heterogeneity in utility, ; is identied by variation in unobserved patient persistence to
either remain or exit the trial, which is constant across time periods.
VI. Results
A. AZT Results
Health Outcomes. Structural parameter estimates are found in Table 3 and treat-
ment e¤ect estimates are found in Table 4. In both models, the estimates on health outcomes
are roughly the same. Liver related side e¤ects appear to occur with the same frequency
across groups at an average rate of 10%. On the other hand, the instance of blood related
side e¤ects does vary across treatment groups. Patients in the low and high dose groups
are 4% and 11% more likely to experience a blood related side e¤ect than patients in the
placebo group, respectively. I would expect blood related side e¤ects to have a relatively
stronger impression on learning than liver related side e¤ects due to the di¤erence in occur-
rence across treatment groups. Another interesting outcome is the treatment e¤ect of AZT.
The treatment e¤ect is found to be positive and statistically signicant, but the magnitude is
small. The dose-e¤ect leads to a 2% improvement in CD4 counts and the time e¤ect is half a
percent increase in each subsequent period. There appears to be a particular match quality
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associated with AZT. The majority of the treatment variation is captured in the patient
specic unobserved heterogeneity. Patient unobserved heterogeneity constitutes 71.1% of
the unobserved health error. When comparing the OLS and structural model estimates,
the largest deviation in estimates is within the placebo health coe¢ cients. OLS states the
improvement in health from placebo is 18% with a time trend that is not statistically di¤er-
ent from zero. The structural model estimates of placebo health are a 9% improvement in
health during the rst eight weeks and a 1.2% decrease in health every 8 weeks thereafter.
The treatment e¤ect estimate across the models is relatively the same, but it should be noted
that the structural model corrects for attrition bias by decreasing the estimated treatment
e¤ect.
Prior Distribution. In both the static and dynamic model, patientsprior on the
treatment e¤ect is initially a negative return followed by an increase in health over time.
The static model provides a very pessimistic view of the treatment e¤ect by suggesting
that AZT would lead to a 350% reduction in CD4 counts with a 1.1% increase over time.
The dynamic model gives an optimistic view with CD4 counts falling by 17% initially, then
rising 215% over time. Given these priors, positive health returns are experienced at week 9.
Though neither model provides estimates of the prior which are close to the actual treatment
e¤ect, both models convey information that patients believe they would become sicker before
they became healthier. The prior variance captures the level of condence patients have
in their prior means. The estimated prior variance terms are small relative to the health
variance, suggesting that patientsposterior treatment e¤ect beliefs would converge slowly
to the actual treatment e¤ect.
Utility Parameters and the Outside Option. The di¤erence in utility parameters
between the two models is small. The coe¢ cient of absolute risk aversion, ; is slightly larger
in the static model (1:2511) than in the dynamic model (1:014). Yet when comparing risk
between patients in the AZT study and the Topamax study, I nd HIV patients to be
more risk averse. This result highlights the di¤erence in severity between the two diseases.
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Though the AZT trial is longer than the Topamax trial, the e¤ect each drug has on utility is
considered over the lifetime of the patient. On average, an HIV patients lifetime is shorter
than that of an alcoholic; therefore, risk is more concentrated for an HIV patient within a
given time frame than that of an alcoholic with the same time frame. Side e¤ect estimates
in the AZT study are very large. The marginal disutility associated with blood related side
e¤ects is a decrease of 166 utils. Liver decreased utility by 64 utils. Experiencing a side
e¤ect essentially pushes patients out of the study. The parameter estimate for "nishing
reward" is 3.2862 utils in the dynamic model and 7.3841 utils in the myopic model. A
positive coe¢ cient for this parameter captures the curvature of the survival function with
respect to time and suggests the survival function is decreasing at a decreasing rate with
time. This result implies that the likelihood of exiting the trial next period decreases the
longer a patient remains in the trial.
For HIV patients the outside option is sparse. In the late 1980s, the only treatment
available was AZT at 100mg doses. The cost of treatment was estimated to be $10,000
annually and AZT could only be obtained with a diagnosis of AIDS. The number of in-
dividuals with AIDS was increasing over this time period, which increased the supply of
AZT and helped improve availability. In order to capture some of these dynamics in the
outside option, I include a set of dummy variables capturing a patients AIDS status and
the calender year. Patients who have AIDS at the onset of the trial have higher values
of the outside option than HIV patients. The value of the outside option improves over
time in a non-linear fashion. The outside option experiences a small increase in 1988 of .31
utils followed by a much larger increase in 1989 of 1.89 utils when the FDA "fast tracks"
the approval of AZT for public consumption. The outside option is also comprised of two
additional components: baseline parameter values and belief dependent parameter values.
The baseline parameter values capture changes in the outside option that are independent
of patient treatment beliefs, such as improvements in medical technology. The baseline
parameter values are initially negative ( 1:4567) relative to the value of participating in the
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experiment, but improve at a rate of 0.5089 every 8 weeks thereafter. The belief dependent
component interacts a patients posterior belief on group assignment, Eit(G = Treat), with
the constant and time trend of the outside option. Patients who place a higher probability
of being in one of the treatment groups nd the outside option less appealing over time.
Holding all things constant, the outside option would imply that the rate of attrition is
decreasing as the patients posterior probability of receiving treatment rises.
Goodness of Fit. The predicted versus observed survival probability is plotted in
Figure 3. The structural model captures 96% of the variation in attrition choices overall.
Over the rst 32 weeks of the trial, the model underestimates the survival probability, but it
performs well thereafter. The model provides a modest t when evaluating survival proba-
bilities within treatment groups. Survival probabilities are overestimated (underestimated)
if the points lie above (below) the x-axis. On average, the model appears to over state
survival probabilities for individuals in the treatment groups and to underestimate survival
probabilities for patients in the placebo group.
Learning. Figure 4 displays the evolution of posterior beliefs by treatment group.
Patients in all groups increase their posterior belief of being in the low dose group throughout
the trial. The largest increase is seen by patients in the high and low dose treatment
groups. The rate of increase di¤ers across groups until week 32 by which time each patient
has received three signals. While it should be intuitive to observe posterior probabilities
increasing for patients in experimental groups, I am puzzled by the consistent increase made
by patients in the placebo group. The same type of behavior is displayed when modelling
posterior probabilities of being in the high dose group. In week 8, 20% of patients believe
they are in the placebo group. This percentage decreases to under 10% by week 16, and
close to zero by week 32. One explanation for these results is the initial strong priors on
the treatment e¤ect. Even in the presence of low returns, patients remain condent that
the treatment e¤ect would be large over time. When the expected large increase in health
does not materialize, patients eventually start to redistribute their beliefs downward toward
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the low dose group.
Treatment e¤ect learning is observed to be slow. Note in gure 5, the posterior means
do approach the actual treatment e¤ect estimates, but they arrive after week 48. Learning,
in the early stages of the trial, is faster for patients in the high dose group, followed by the
low dose group. The posterior treatment e¤ect mean falls relatively faster for patients in
the high dose group, which indicates a faster rate of learning. Overall, learning in this trial
is slow. At the end of the trial, patients in all treatment groups place about a 50% chance
of being in either the high or low dose groups and the posterior treatment e¤ect mean dose
not signicantly vary between groups.
To further explore the slow learning rate, the structural dynamic model is used to
simulate the evolution of patient beliefs in a ctitious clinical trial lasting 288 weeks (instead
of 80 weeks as in the original trial). Extending the length of the trial to 288 weeks
provides patients with more than three times the number of possible signals generated in
the original trial. As in the shorter experiment, treatment e¤ect beliefs tended to rise
above the estimated treatment e¤ects early in the trial. After week 32, patients adjusted
their beliefs downward and eventually "over shoot" the estimated treatment e¤ect. After
week 96, treatment e¤ect beliefs increased slowly towards the estimated treatment e¤ect
and remained positive for all treatment groups24. Coincidentally, patient group beliefs in
the simulated experiment do not converge to their actual treatment assignments as would
be predicted with a typical model of Bayesian Learning. Instead, posterior group beliefs
remain constant with beliefs being equally divided between the low and dose groups.
In the AZT experiment, the estimated treatment e¤ect is close to zero making it
di¢ cult for patients to distinguish between placebo and AZT generated health signals. For
this reason, a patients posterior group belief converges slowly (if at all) to the patients
actual treatment group assignment. It is possible in this model for posterior treatment
e¤ect beliefs to converges towards the within group treatment e¤ect without converging in
group assignment beliefs. When this occurs the treatment e¤ect becomes a weighted average
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of health signals and priors from all the treatment groups.
Decomposing Patient Attrition. The model of patient behavior allows for changes
in side e¤ects, learning, and the value of external options to a¤ect patient attrition. In this
section, I isolate the contribution towards attrition made by these three components. In
the model, side e¤ects have both an implicit and explicit e¤ect on attrition. Implicitly, side
e¤ects help patients to infer their true group assignment. Explicitly, side e¤ects may be
considered the price or direct cost of consuming the experimental drug. I evaluate these
two components separately. To capture the explicit cost of side e¤ects on attrition, patient
behavior is simulated restricting the parameters on side e¤ect sensitivity, a1 = 0 and a2 = 0,
to zero. From these results, I compare hazard rates between the restricted outcome and the
unrestricted structural parameters (see table 5). Side e¤ects account for a 19% increase in
attrition during the rst eight weeks, 14% the next eight weeks, but reduces down to 1% by
week 64. The diminishing e¤ect of side e¤ects on attrition is consistent with having fewer
unhealthy patients in the trial as time increases.
The same method is used to nd the e¤ect of the outside option on attrition. The
outside option parameters (except for those interacted with group beliefs) are set to zero
and hazard rates are computed. The value of the outside option includes increased access
to AZT, lower cost of care, and improvements in medical technology. On average, the
outside option reduces the sample size by about 3% every eight weeks. There is one notable
deviation at week 16 associated with the approval of AZT as a treatment for individuals
with AIDS.
The e¤ect of learning on attrition is found by di¤erencing the overall hazard rate with
the side e¤ect and the outside option hazard rates. Initially, learning decreases attrition.
The benet received from reducing uncertainty is greater than the cost of remaining in the
trial. These benets peak in week 16 where learning decreases attrition by 5.4%. The
returns from learning begin to diminish in the later periods where the marginal benet of an
additional signal is decreasing. Learning becomes the dominant e¤ect causing attrition in
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the last two periods of the experiment. Table 5 displays how hazard rates change throughout
the trial across the three components.
The e¤ect of learning can further be disaggregated into learning from health signals
and side e¤ects. In clinical trials, the practice of altering the placebo to display side
e¤ects is becoming more accepted. The motive is to minimize patient learning derived from
di¤erences in side e¤ect intensity between the control and experimental drug. To separate
the explicit and implicit e¤ect of side e¤ects on attrition, I simulate patient behavior under
the restriction that placebo side e¤ects are equal to the low dose treatment side e¤ects25.
Hazard rates are then calculated using the previously described method. The results suggest
that if the di¤erence in side e¤ect intensity is removed, then more learning increases attrition.
The mean hazard rate of learning on attrition without side e¤ects is a 4.3% decrease in the
sample each evaluation period (8 weeks). The di¤erence in the learning hazard rate with
and without side e¤ect is on average a 3.5% decrease in attrition. Therefore, the implicit
e¤ect of side e¤ects is a 0.8% decrease in attrition. Clinical trial designers must then face a
trade-o¤between heterogenous attrition rates when the placebo is not altered, and increased
overall attrition when the placebo is altered.
B. Topamax Results
Health Outcomes. In this section, I present estimates of the structural parameters
for the Topamax study found in Tables 6 and 7. Two models of behavior are estimated to
provide a comparison between the "forward looking" patient and the myopic patient. In
the dynamic (static) model, the weekly discount factor is xed at  =.98 ( = 0). To allow
for comparisons between models, the static model of attrition is estimated as a standard
logit, where the variance of the extreme value error is set equal to the estimated variance
of the extreme value error in the dynamic model. First consider the health outcome para-
meter estimates. In both models, the estimates on health outcomes are roughly the same.
Individuals in the treatment group are 4% more likely to experience fatigue (side e¤ect 1)
27
and 10% more likely to experience parathesia (side e¤ect 2) than individuals in the placebo
group. Given these estimates on side e¤ect experiences, I would expect parathesia to better
convey group assignment, as the di¤erence in means between treatment groups is greater
than the side e¤ect of fatigue.
The estimated health coe¢ cients represent the marginal e¤ect of each explanatory vari-
able on the natural logarithmic change in health ( log(GGT ))26. Initially, patients in the
Topamax group experience a 6% (TE) increase in GGT levels relative to patients in the
placebo group, but in each subsequent period, GGT levels fall 7% (TE Time) faster in the
Topamax group than in the placebo group. Unobserved heterogeneity in health between
patients is primarily driven by the patient specic error. Patient unobserved heterogeneity
constitutes 70.5% of the unobserved health error. When comparing the OLS and structural
model estimates, the largest di¤erence in coe¢ cients is the treatment-time e¤ect. The
reduced form model is found to underestimate the time-treatment e¤ect component, but the
di¤erence is not statistically signicant. The point estimate for the treatment-time e¤ect
in the structural model is twice the size of the OLS estimate. The estimated treatment-
time e¤ects by model are OLS  0:0276 ( 0:0548; 0:0004) and structural model  0:074
( 0:1159; 0:0321)27. The lack of statistical support of attrition bias may be attributed to
a relatively small sample size (148 patients in the Topamax study).
Prior Distribution. The estimated prior distribution of the treatment e¤ect pro-
vides insight on a patients level of optimism (or pessimism) for participating in the trial.
In the dynamic model, the estimated health priors suggest patients believe the experimental
drug will lead to an initial 13% increase in GGT levels, followed by a 69% decrease in each
subsequent week when compared to GGT levels in the placebo group. Given these esti-
mates, patients in the experimental group expect an improvement in their health status after
1.17 weeks of participating in the trial. On the other hand, the estimated treatment e¤ect,
found using observed health outcomes, suggests health status improves after 1.86 weeks of
participation for patients in the experimental group. This result implies patients are initially
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optimistic about the potential health benets associated with the experimental drug.
Utility Parameters and the Outside Option. The largest di¤erences between the
dynamic and myopic models are found in the estimates for the utility parameters and the
outside option. The utility function parameters capture a patients sensitivity to changes
in risk, income, and side e¤ect experiences. Sensitivity to risk is captured by the coe¢ cient
of absolute risk aversion, . Patients are less risk averse in the dynamic model ( = 0:1240)
than in the myopic model ( = 0:3634). This result is consistent with economic theory
in that the forward looking patient spreads her risk over current and future periods. The
myopic patient concentrates risk in the current period. In the same light, the side e¤ect
parameters are smaller in the dynamic setting than in the myopic setting. The direct
e¤ect of side e¤ects is concentrated in the current period for the myopic patient, but spread
across current and future periods for the forward looking patient. As previously argued
in the introduction of this paper, side e¤ects experienced in the Topamax study are better
tolerated than side e¤ects experienced in the AZT study. Evidence of this is found in the
sign of the coe¢ cient of parathesia (side e¤ect 2). Parathesia leads to an increase in utility
of 9:4456 utils in the dynamic model and 9:969 utils in the myopic model. I suspect that this
parameter is adjusting for spillover learning e¤ects not already captured within the model.
Fatigue (side e¤ect 1) leads to a disutility of 4:6825 utils in the dynamic model and 6:892
utils in the myopic model.
The model captures a patients response to compensation by estimating a patients
income elasticity. In the dynamic setting, a patients utility is inelastic to changes in
income. A 1% increase in income leads to a 0.59% increase in utility. In the myopic setting,
the e¤ect of compensation on attrition is strong. A 1% increase in income leads to a 7.9%
increase in utility. The large di¤erence in income elasticity between the two models displays
the sensitivity of parameter estimates with respect to the discount factor28.
Lastly, I include an additional parameter in the last period utility function, UT (), to
capture any unobserved benets (or costs) from completing the trial. In some experiments,
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patients are rewarded for completing the trial by receiving a free supply of the actual exper-
imental treatment regardless of group assignment. The parameter estimate for "nishing
reward" is 17:2976 utils in the dynamic model and 4:4037 utils in the myopic model. A
positive coe¢ cient for this parameter captures the curvature of the survival function with
respect to time and suggests the survival function is decreasing at a decreasing rate with
time. This result implies that the likelihood of exiting the trial next period decreases the
longer a patient remains in the trial.
The outside option is an important component of attrition because it captures the pa-
tients opportunity cost of remaining in the trial. The outside option can be decomposed
into two parts: external options and longer term cost of participation. The outside option
can include a large range of external options including detoxication clinics, support meet-
ings, or drinking. The outside option also internalizes long term e¤ects of the experimental
drug on health even after the patient has stopped taking the drug. The study dataset does
not contain information on patient choices after exiting the trial. Therefore, the model takes
a simplistic approach in handling external options, but the second component of the outside
option is captured by allowing a patients group assignment belief to change her valuation of
the outside option. The outside option constant represents the benet measured in utils of
exiting the trial the rst period. In both the dynamic model and myopic model, the value
of the outside option constant is initially negative (dynamic model = -0.0905 and myopic
model = -1.1549), but the outside option improves quickly in subsequent periods (dynamic
model = 0.0501 and myopic model = 1.7417). When the outside option parameters are
interacted with the patients subjective probability of being in the treatment group, Eit(G =
Treat), then the initial value of the outside option increases (dynamic model = 0.1734 and
myopic model = 0.3699). The time-belief component of the outside option di¤ers in the
two models. The dynamic model nds a decreasing e¤ect on the outside option ( 0:3014)
as beliefs and time increase. Patients who believe they are actually receiving treatment
are less likely to exit the trial. The myopic model nds an increasing e¤ect on the outside
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option (1:304) as belief and time increase. Patients who believe they are actually receiving
treatment are more likely to exit the trial. Again, this divergence in the estimated parame-
ters is tied to the discount factor. Including patient demographics in the outside option and
using a heterogenous discount factor may alleviate this problem.
Goodness of Fit in Survival Rates. The dynamic models ability to explain patient
behavior is measured by using the estimated structural parameters to simulate attrition
decisions, then compare these outcomes with observed decisions in the experiment. First, I
use the original GGT values for each patient found at the beginning of the trial as a starting
point on health histories. To capture unobservable health shocks, I draw 10 patient specic
errors using the estimate of unobserved health heterogeneity and a four random health
shocks from the estimate of the regression/learning parameter. Conditional on a patients
original GGT value at the start of the trial, I use these simulated unobservable errors in
conjunction with the patients group assignment, estimated treatment e¤ects, and health-
side e¤ect covariance matrix to complete a patients health and side e¤ect history29. Next, I
simulate a set of unobservable utility shocks. The utility shocks consist of a patient specic
error and the extreme value error. I simulate 10 patient specic utility errors from a normal
distribution with variance equal to the estimated variance of the unobserved heterogeneity
in the utility function. The second utility shocks are drawn independently across patients
and time from an extreme value distribution with variance equal to (b)2 =6: The simulated
health histories and unobservable errors are then used to solve each patients value function.
If a patients value function is > 0, then the patient remains in the trial; otherwise, the
patient exits the trial. Figure 6 exhibits the observed survival rate versus the predicted
survival rate for each period. The dynamic model explains 98.4% of the variation in overall
survival (attrition) rates, but precision is lost when evaluating predicted survival rates by
group. The model captures 92% of the variation in survival rates within the placebo group,
but only 56% for the experimental group30. The model underpredicts survival rates in the
experimental group and overpredicts survival rates in the placebo group. I suspect that the
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lack of precision on survival probabilities may be related to non-compliant behavior. While
consuming less pills reduces the e¤ect on health, it also mitigates the disutility from side
e¤ects. Ignoring non-compliant behavior may overstate the e¤ect of side e¤ects on attrition;
thus, leading to the divergence between predicted and observed survival probabilities.
Learning . The model captures learning in two parts: (1) Posterior Group Assign-
ment Beliefs and (2) Posterior Expected Treatment E¤ect. Simulation methods are used
to quantify the two parts. Using the estimated structural parameters from the dynamic
model, I simulate patient behavior and record the evolution of patient beliefs in each period.
Figure 7 demonstrates the evolution of group assignment beliefs and treatment e¤ects for
both placebo and experimental patients. The vertical axis captures the mean Bayesian
probability of being in the treatment group and the x axis measures treatment periods. Ini-
tially, Bayesian beliefs on receiving active treatment decrease in both groups. This result is
consistent with having optimistic beliefs. The decrease in subjective treatment probability
is greater in the placebo group than the experimental group. While both groups are disap-
pointed with their health outcomes, the experimental group receives a modest return, thus
placing a higher probability of being in the experimental group than the placebo patients.
The second component of learning is the evolution of the posterior treatment e¤ect. The
posterior treatment e¤ect is Eit (gt) =
hP
j=1
Hjf (dit;Hit;Sit) where H is a 1xh vector of
health states and f (dit;Hit;Sit) is the discrete posterior distribution of health states, which is
dependent upon a patients health history, side e¤ect history, and prior on group assignment.
The posterior mean represents the weighted mean of posterior treatment e¤ect beliefs where
a patients belief on treatment group assignment serve as the weights. In period zero,
the posterior mean for both groups is equal to (:5) (prior TE constant) + (:5) 0 = 0:06635
where the placebo treatment e¤ect is xed at zero. I include the estimated treatment e¤ect
(TE) for the experimental group as a guide (the "treatment e¤ect" in the placebo group
is zero). Ideally, learning would produce posterior treatment e¤ect beliefs close to the
estimated treatment belief in the experimental group and posterior beliefs close to zero in
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the placebo group. Patients in the experimental group are observed to have posterior means
relatively closer to the estimated experimental treatment e¤ect after receiving three signals,
but placebo patients have posterior means relatively far from zero after three signals.
There are several points to be made from this result. First, the two dimensional
learning model proposed in this paper can capture slow learning. The traditional model
of Bayesian learning where each signal is equally weighted by construction forces the rst
signal to have the largest marginal e¤ect on posterior beliefs. To a naive reader, it may be
easy to confuse faster learning with a result that is actually driven by functional form. The
two dimensional model can capture slow learning by allowing signals to be weighted using
posterior beliefs on group assignment. In this study, the largest marginal improvement
in information occurs in the second signal for patients in the experimental group and the
last signal for placebo patients. Next, it is observed that patients in the placebo group
are relatively faster learners about group assignment, but slower learners about treatment
e¤ects. I suspect that this result is driven by the statistically signicant pharmacological
e¤ect of the experimental drug. The experimental drug generates a strong enough e¤ect,
allowing patients to separately identify the treatment e¤ect from random health shocks.
Convergence: Topamax. As described in the previous section, the additional uncer-
tainty associated with random group assignment causes patient learning to converge slowly
toward the estimated treatment e¤ect. To illustrate this point, the structural dynamic
model is used to simulate the evolution of patient beliefs in a ctitious clinical trial lasting
30 weeks (instead of 12 weeks as in the original trial). Extending the length of the trial
to 30 weeks provides patients with more than three times the number of possible signals
generated in the original trial. Figure 8 displays the results of this experiment. Patients
in the placebo group do not receive an active drug, therefore the treatment e¤ect in this
group is zero. The placebo group does converge towards a treatment e¤ect of zero, but
does not converge on group assignment. In week 3 the posterior di¤erence in log health
is -0.22, but the posterior treatment e¤ect mean plateaus at week 12 and remains constant
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thereafter at -0.044. The posterior probability of being in the placebo group for placebo
patients reaches 75% in week 9, but decreases at a decreasing rate through the remainder of
the experiment with a minimum of 40%. The divergence in the posterior group belief is
related to the movement of the posterior treatment e¤ect for placebo patients towards zero.
As the posterior treatment e¤ect approaches zero, it becomes more di¢ cult for the patient to
distinguish between signals generated from a non-active drug (placebo) or an experimental
drug that has a low return (TE close to zero).
Topamax patients experience convergence in both the treatment e¤ect and group assign-
ment. On the posterior probability of being in the experimental group, Topamax patients
reach a low of 31% in week 12, but posterior probability reaches a maximum of 73% in
week 3031. On the posterior treatment e¤ect, the largest di¤erence between the estimated
treatment e¤ect and the Bayesian posterior mean occurs in week 3 when the estimated e¤ect
is a 1.2% decrease in GGT and the posterior treatment e¤ect is a 22% decrease in GGT.
The posterior mean begins to converge towards the estimated treatment e¤ect at week 12.
In the last week of the experiment, the di¤erence between the estimated and posterior treat-
ment e¤ect is reduced to 7 percent. These results reinforce the ndings from the previous
section that treatment group uncertainty persist, thus leading to a slower rate of learning
than would be found when treatment assignment is ignored.
Decomposing Patient Attrition. Using the same methods described in the AZT
section, I decompose the e¤ects of side e¤ects, learning, and the value of external options
on patient attrition (see table 8). Two types of side e¤ects are considered in the Topamax
study, parathesia and fatigue. Both side e¤ects are found to have a trivial explicit e¤ect on
attrition. The mean hazard rate associated with side e¤ects is a 0.1% decrease in attrition.
On the other hand, the outside option is found to have a strong negative e¤ect on attrition
rates. With the exception of week 9, the outside option decreases attrition by an average of
4%. The e¤ect of learning on attrition is found by di¤erencing the overall hazard rate with
the side e¤ect and the outside option hazard rates. Learning is the dominant component of
34
attrition in the Topamax trial. Initially, learning increases attrition by 18.5%, but the e¤ect
of learning on attrition is diminishing. In week 12, the learning hazard rate has decreased
to an 11% increase in attrition rates. The learning hazard rates suggest that patients are
more likely to exit the trial early when returns are low instead of waiting for more signals to
reduce uncertainty.
To separate the explicit and implicit e¤ects of side e¤ects on attrition, I simulate patient
behavior under the restriction that placebo side e¤ects are equal to treatment side e¤ects.
Hazard rates are then calculated using the previously described method. The mean hazard
rate of learning on attrition without side e¤ects is a 13.5% decrease in the sample each
evaluation period (3 weeks). Learning without side e¤ects causes more early attrition, but
the mean e¤ect over the duration of the trial is virtually the same as the learning hazard
with side e¤ects (13.51% w/o side e¤ects and 13.49% with side e¤ects).
VII. Limitations
In this section, I identify limitations of the model in capturing all observable patient
behavior. These limitations can be categorized into two groups: model limitations and data
limitations. The structural model imposes several assumptions about patient behavior and
the pharmacology of the experimental drug. First, patients are assumed to be risk averse
with a specic type of utility function. The constant absolute risk aversion utility function
provides a convenient analytical specication, but tends to overstate risk aversion. The
consequence is an overestimate of attrition rates. Second, estimation of dynamic models are
computationally expensive. To alleviate the computational burden, I restricted both the
number of side e¤ects used to two and the severity of these side e¤ects to a binary variable.
The trade-o¤ of a small state space is loss of statistical e¢ ciency. Third, a linear function
(containing a constant and a slope term) is adopted to capture the pharmacological e¤ect
of the experimental drug. A more exible function would capture more of the variation
in health outcomes, but would require the model to capture patient learning over these
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additional parameter values, which would further increase the computation burden.
With respect to data limitation, I focus on limitations associated with experimental
design and survey collection. In experimental design, clinical trials commonly use small
samples (typically fewer than 100 observations), which leads to poor estimates of the struc-
tural parameters. Further, a sample selection problem arises at the onset of the trial. The
subset of patients from the population are generally not representative of the population.
Instead, these patients are typically poor or very unhealthy. For this reasons, the estimated
treatment e¤ect should be viewed as the improvement in health for this subset of patients
and not the general public. In survey design, there exist several variables of interest to an
economist, which may not typically be recorded by the health researcher. Two examples
are the availability of alternative treatments and the cost of care to treat the disease in
the absence of the clinical trial. These variables dene the patients opportunity cost for
participating in the trial. A set of variables capturing the choice of entering the trial would
alleviate the self selection problem and improve estimates on patients priors. Information
pertaining to how the patient becomes aware of the trial would also be useful to estimate
a patients prior. A patient who is introduced to the experiment by her physician may
have higher priors than if she receives the same information from a newspaper ad. Lastly,
collecting subjective group probability from each patient throughout the trial could be used
to measure the "goodness of t" in the model.
VIII. Conclusion
In this paper, I provide an empirical examination of learning under ambiguity in the
context of clinical trials. A structural model of patient behavior is adapted to include a
two dimensional model of Bayesian learning. The model captures patient learning of the
experimental drugs treatment e¤ect despite ambiguity of treatment group assignment. The
structural model is estimated using data from two clinical trials, a Topamax study and
an AZT study. These clinical trials o¤er a comparison between a drug with strong side
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e¤ects used to treat HIV and a drug with few side e¤ects used to treat alcoholism. In both
studies, patient learning is found to be slow. In neither study did the patientsposterior
on group assignment converge to the actual assignment by the end of the trial. Posterior
treatment e¤ects appear to initially diverge from estimated treatment e¤ects in both trials,
but slowly converge to the estimated treatment e¤ect in subsequent periods. The fastest
rate of learning is found in the treatment group of the Topamax study. After 12 weeks in
the study, the posterior treatment e¤ect of patients in the treatment group converges to the
estimated treatment e¤ect, but uncertainty about treatment assignment persists.
The prior distribution on treatment e¤ects reveals that patients are initially optimistic
about the experimental drug. In the Topamax study, the prior distribution implies that
positive returns are expected in week 1.17, but in reality the positive returns occur at 1.87
weeks. In the AZT study, the prior distribution indicates a short run decrease in health
followed by a strong long run increase in health. The estimated prior distribution implies
that patients view AZT as a cure for HIV. Patients expect a positive returns in week 9 of
the study. The estimated treatment e¤ect indicates that positive returns occur immediately,
but the magnitude of the treatment e¤ect is much smaller than the prior treatment e¤ect
mean implies.
Attrition bias is present in both experiments. In the Topamax study, OLS coe¢ cient
estimates under-state the treatment e¤ect. The estimated treatment e¤ect in the structural
model is more than two times the magnitude of the OLS estimates. In the AZT study,
the least squares estimates on placebo health are underestimated when compared to the
structural results. The least squares estimate of placebo health, an 18% improvement in
health, is twice as large as the structural model estimate, a 9% improvement. To mitigate
some of the problem associated with attrition, I perform a counter-factual experiment that
increases the probability of being randomized into a treatment group. Patients in the
Topamax study are insensitive to changes in the randomization probability. Increasing the
randomization probability by 0.1 leads to a 0.3% decrease in overall attrition. On the other
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hand, attrition in the AZT study decreases by 1.1% with a 0.1 increase in the randomization
probability. Patients in the placebo group are the most responsive in this regard because
attrition rates are decrease by 1.7% for the same change in the randomization probability.
The proposed model can be modied to capture other aspects of learning. Specically,
a patients prior distribution on the treatment e¤ect can be modelled to vary with patient
demographics. The prior distribution may also vary by di¤erent types of advertisement
used to recruit patients. Patients who are recruited via physicians advice may have much
higher priors about the treatment e¤ect than those patients recruited via newspaper ads.
In addition, the subject of learning under ambiguity is not limited to clinical trials, but may
be applied in many other topics of interest for the economist. In the area of education,
the study of student attrition from college courses could be viewed as learning ones ability
(treatment e¤ect) to perform well in a class given the ambiguity of a teachers quality (group
assignment).
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Tables
Table 1: ACTG 019 Descriptive Statistics
Variables
Placebo
Mean STD
Low Dose
Mean STD
High Dose
Mean STD
Black .07 .26 .10 .30 .13 .34
Female .09 .29 .07 .26 .08 .27
Hispanic .10 .30 .09 .29 .10 .30
Age 34.74 7.77 34.93 8.23 34.72 8.08
Weight 166.57 24.91 164.62 26.86 167.34 30.09
Hemoglobin 14.67 1.1 14.58 1.12 14.69 1.18
Platelets 225.46 59.94 219.53 53.73 223.20 55.76
Granulocytes 2947.49 1229.32 2820.63 1042.17 2928.29 1059.3
Homosexual 0.73 0.44 0.72 0.45 0.72 0.45
Bisexual 0.14 0.35 0.21 0.41 0.18 0.38
IV Drug Use 0.11 0.31 0.06 0.24 0.07 0.26
CD4 373.48 163.66 383.61 172.8 379.88 163.92
Blood 0.0167 0.3389 0.0183 0.2952 0.068 0.5646
Liver 0.0365 0.5151 0.0464 0.5787 0.0257 0.5064
AIDS 0.1023 0.3031 0.142 0.3491 0.1148 0.3189
Duration (weeks) 37.63 27.31 34.10 26.58 28.70 25.42
N 428 453 456
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Table 2: Patient Characteristics
Variable Placebo Topamax ALL
AGE 42.07 41.51 41.79
BMI 26.57 25.67 26.12
Female 0.27 0.31 0.29
Yrs. School 13.55 13.51 13.53
Income last 30 Days 3279.65 3391.43 3335.54
Base line GGT 65.31 81.8 73.55
End GGT 52.52 57.83 55.18
AVG Survival (weeks) 5.92 6.72 6.32
N 75 75 150
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Table 3: Structural Param eters: ACTG 019 Study
Prior D istribution of Treatm ent E¤ects (TE) Dynam ic Static U tility Param eters Dynam ic Static
Prior TE Dose
-0 .1767a
(0 .0165)
-3 .5022a
(0 .0205)
Utility : Unobserved Heterogeneity
0.003a
(4 .09E -06)
0.0030a
(3 .7E -05)
Prior TE T im e
2.1596a
(0 .0162)
0.0111
(0.0127)
Coef. o f Absolute R isk Aversion
1.014a
(0 .0123)
1.2511a
(0 .0151)
Prior Variance (TE dose)
0 .0048a
(8 .2E -05)
0.2893a
(0 .0035)
S ide E¤ect 1 Sensitiv ity
166.1292a
(0 .0122)
169.6744a
(0 .0121)
Prior Variance (TE T im e)
0.2564a
(0 .0054)
0.7454a
(0 .0090)
S ide E¤ect 2 Sensitiv ity
64.2802a
(0 .0122)
82.8041a
(0 .0135)
F in ish ing reward
3.2862a
(0 .0122)
7.3841a
(0 .0226)
Tau
57.3458a
(0 .711)
57.3458
(fixed)
Health Outcom es Param eters Dynam ic Static Outside Option Param eters Dynam ic Static
Health Variance
0.0453a
(0 .0009)
0.0449a
(0 .0011)
Outside Option Constant
-1 .4567a
(0 .0163)
-87.8342a
(0 .0128)
Health : Unobserved Heterogeneity
0.1114a
(0 .0036)
0.1118a
(0 .0019)
Outside Option T im e
0.5089a
(0 .0158)
0.0291a
(0 .0134)
B lood Side E¤ects: P laceb o
0.1435a
(0 .0015)
0.1450a
(0 .0063)
Outside Option Eit(Dose =1)
-0 .3755a
(0 .0139)
-2 .8339a
(0 .0122)
L iver S ide E¤ects: P laceb o
0.1048a
(0 .0011)
0.1051a
(0 .0035)
Outside Option Eit(Dose =1)*T im e
-0.1265a
(0 .0159)
-11.3141a
(0 .0133)
B lood Side E¤ects (Dose =1)
0.1841a
(0 .0018)
0.1805a
(0 .0049)
Outside Option Eit(Dose =3)
0.3802a
(0 .0124)
-10.2138a
(0 .0121)
L iver S ide E¤ects (Dose =1)
0.0971a
(0 .001)
0.0981a
(0 .0019)
Outside Option Eit(Dose =3)*T im e
-1.3831a
(0 .0139)
-3 .5557a
(0 .0183)
B lood Side E¤ects (Dose =3)
0.256a
(0 .0025)
0.2547a
(0 .0048)
A IDS Dummy
0.286a
(0 .0177)
-0 .9332a
(0 .0121)
L iver S ide E¤ects (Dose =3)
0.1171a
(0 .0012)
0.1157a
(0 .0054)
Year 88 Dummy
0.31a
(0 .0143)
-66.5812a
(0 .0151)
Variance S ide E¤ect 1
0.154
(0.1044)
0.1530a
(0 .0200)
Year 89 Dummy
1.86a
(0 .0268)
1.2397a
(0 .0255)
Variance S ide E¤ect 2
0.0947
(0.2514)
0.0948a
(0 .0174)
D iscount Factor B = .98 (xed) B = 0 (xed)
Cov(Health ,S ide E¤ect 1)
-0 .0087
(0.0058)
-0 .0091
(0.0126)
Log L ikelihood Value -6785.6339 -6812.8377
Cov(Health , S ide E¤ect 2)
-0 .0029
(0.0049)
-0 .0030
(0.0113)
F 54.4076
a
Cov(S ide E¤ect 1, S ide E¤ect 2)
0.0554a
(0 .105)
0.0553a
(0 .0126)
N 1337
standard errors are in parenthesis, each dose level is equal to 500mg of AZT
F test: L ikelihood ratio test (dynam ic vs static)
a= Sign icant at 99% b= Sign icant at 95% c= Sign icant at 90%
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Table 4: AZT Health Parameters
VARIABLES OLS Structural
Constant 0.1829
a
(0.0149)
0.0895a
(0 .0133)
Time -0 .0092
a
(0.0043)
-0 .0121a
(0 .0038)
Dose 0.0149
(0.0082)
0.0189a
(0 .0063)
Time*1(Dose=500mg) 0.021
a
(0.005)
-
Time*1(Dose=1500mg) 0.011
(0.0072)
-
Time*1(AZT) - 0.0045
(0.0041)
AIDS -0 .6617
a
(0.0228)
-
a
=1% ,
b
= 5% level of sign icance
Table 5: Hazard Rate - AZT
week 8 16 32 48 64 80
Side E¤ects -0.1961 -0.1376 -0.0377 -0.0337 -0.0104 0.0599
Outside Option -0.0352 -0.0842 -0.0285 -0.0294 -0.0122 -0.0247
Learning 0.0151 0.0544 0.0174 0.0127 -0.0434 -0.1074
Learning without Side E¤ects -0.0643 0.0088 0.0105 -0.0119 -0.0686 -0.1364
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Table 6: Structural Param eters: Topamax Study
Prior D istribution of Treatm ent E¤ects (TE) Dynam ic Static U tility Param eters Dynam ic Static
Prior TE constant
0.1327a
(0 .0442)
-1 .5686a
(0 .1035)
Utility : Unobserved Heterogeneity
1236.57a
(55.65)
747.92a
(210.54)
Prior TE T im e
-0.6908a
(0 .0482)
6.0883a
(0 .0441)
Coef. o f Absolute R isk Aversion
0.1240a
(0 .0055)
0.3634a
(0 .0996)
Prior Variance (TE constant)
0 .2814a
(0 .0125)
0.5287a
(0 .0233)
Incom e E lastic ity
0.5933a
(0 .0477)
7.9407a
(0 .5737)
Prior Variance (TE T im e)
0.0614a
(0 .0027)
0.4928a
(0 .0297)
S ide E¤ect 1 Sensitiv ity
4.6825a
(0 .0442)
6.892a
(0 .0497)
Health Outcom es Param eters Dynam ic Static S ide E¤ect 2 Sensitiv ity
 9.4456a
(0 .0441)
-9 .969a
(0 .0597)
Health Variance
0.0388a
(0 .0018)
0.0389a
(0 .003)
F in ish ing reward
17.2976a
(0 .0441)
4.4037a
(0 .1238)
Health : Unobserved Heterogeneity
0.0930a
(0 .0044)
0.0935a
(0 .0125)
Tau
18.4968a
(0 .9137)
18.4968
(xed)
P laceb o Side E¤ect 1 M ean
0.1016a
(0 .0040)
0.101a
(0 .018)
Outside Option Param eters Dynam ic Static
P laceb o Side E¤ect 2 M ean
0.0427a
(0 .0018)
0.0386a
(0 .015)
Outside Option Constant
-0 .0905
(0.0596)
-1 .1549a
(0 .462)
Treatm ent S ide E¤ect 1 M ean
0.1487a
(0 .0059)
0.1505a
(0 .0098)
Outside Option T im e
0.0501
(0.1082)
1.7417a
(0 .3942)
Treatm ent S ide E¤ect 2 M ean
0.1489a
(0 .0056)
0.149a
(0 .011)
Outside Option Eit(G = Treat)
0 .1734a
(0 .0641)
0.3699a
(0 .0703)
Variance S ide E¤ect 1
0.1103a
(0 .0204)
0.1104a
(0 .0205)
Outside Option Eit(G = Treat)*T im e
-0.3014a
(0 .0553)
1.304a
(0 .4023)
Variance S ide E¤ect 2
0.0866a
(0 .0202)
0.0863a
(0 .021)
D iscount Factor
0.98
(xed)
0
(xed)
Cov(Health ,S ide E¤ect 1)
0.0034
(0.0056)
0.0033
(0.0073)
Log L ikelihood Value -514.1299 -516.1637
Cov(Health , S ide E¤ect 2)
 0.0055
(0.0051)
-0 .0057
(0.0067)
F 4.0676
b
Cov(S ide E¤ect 1, S ide E¤ect 2)
0.0527a
(0 .0193)
0.0528a
(0 .0199)
N 148
standard errors are in parenthesis
F test: L ikelihood ratio test (dynam ic vs static)
a= Sign icant at 99% b= Sign icant at 95% c= Sign icant at 90%
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Table 7: Topamax Health Parameters
Variables OLS Structural
Constant -0 .1804
(0.0508)
a -0 .1837a
(0.0379)
Time -0 .0035
(0.0105)
-0 .0232
(0.0218)
Treatment Constant 0.0656
(0.0692)
0.0621
(0.075)
Treatment Time -0 .0276
(0.0139)
b -0 .074a
(0.0214)
a
=1% ,
b
= 5% level of sign icance
Table 8: Hazard Rate - Topamax
week 3 6 9 12
Side E¤ects -0.0011 0.0027 0.0089 -0.0047
Outside Option 0.0506 0.0402 0.0008 0.0623
Learning -0.1855 -0.1292 -0.114 -0.1106
Learning without Side E¤ects -0.2093 -0.1222 -0.1006 -0.1086
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Appendix: Discretization Method
The learning model present in this paper requires that patients beliefs on health out-
comes follow a normal mixture model32. The model is a linear
G=3X
j=1
igt
Z
2
 (Hit;Sitj;
; bg; lg)
 
jigt;; igt = 1

d s:t:
G=3X
j=1
igt = 1
combination of G normal distributions where the linear weights, igt, must sum to one. Un-
fortunately, a closed form solution to the posterior distribution of the unknown distribution
parameters in a normal mixture model does not exist. Still, the posterior distribution may
be approximated by discretizing the probability states space conditional on a patients prior
beliefs. A patients prior on treatment group assignment is ig0 = 1=G, which is provided
to the patient by the clinical trial investigators. The patient also forms priors on the
experimental e¤ect. These priors are assumed to be normally distributed.
(A2) ig0 =

1i0
2ig0

~N
0B@
g0
=

10
2g0

; =
26421 0
0 22
375
1CA
Initially, the priors on the dose e¤ect, 1i0, and the treatment time trend, 2ig0, are as-
sumed to be independent. Therefore, A2 can be decomposed into two univariate normal
distributions. I then select a set of discrete values for 1 and 2;  = [ 2; :0; ::2] ; where
i = 10+(i)1: Each discrete value of the experimental e¤ect is separated by one standard
deviation. The probability mass function of  is dened as
Pr(ij10; 1) =

 
i +
1
2
  10

=1
    i   12   10 =1P

 
j +
1
2
  10

=1
    j   12   10 =1
where  () is the normal cumulative density function. An analogous equation denes the
probability mass function for 2: These probability mass functions discretize a patients
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prior belief on the experimental e¤ect and their treatment group assignment.
Given the set of possible experimental e¤ects, equation A1 can be discretize over health
outcomes state space. A patients health is dened as a vector containing CD4 counts, blood
related side e¤ects, and liver related side e¤ects. Initially, the side e¤ect state space takes on
a simple denition: 1 if a side e¤ect is experienced and 0 otherwise33. Both blood and liver
side e¤ects are dened in this manner. CD4 counts are discretize into 10 equispace values
over the sample range of CD4 counts. Therefore, the health outcomes state space for a given
value of ; side e¤ect means (bg; lg), and treatment group assignment is S=(10) (2) (2) = 40:
The rectangular area dened by  (Sj; bg; lg) is found utilizing the multivariate normal
cumulative density function in the MATLAB programming language. The joint distribution
of health outcomes and beliefs is then found by evaluating the 40 health outcome states for
each experimental e¤ect and treatment group state. The total probability space is then
(# of health states)x (# of experimental e¤ect states)x (# of Groups) = 3000, which must
be carried in memory for each patient.
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